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Background:  In  Switzerland,  the  heptavalent  (PCV7)  and  13-valent  pneumococcal  conjugate  vaccine
(PCV13)  were  recommended  for  all infants  aged <2  years  in 2007  and  2011,  respectively.  Due to  herd
effects,  a protective  impact  on  the  invasive  pneumococcal  disease  (IPD)  rates  in adults  had  been expected.
Methods: Within  this  study,  data  from  the nationwide  mandatory  surveillance  was  analyzed  for  all
adult  patients  ≥16  years  with  IPD of  known  serotype/serogroup  during  2003–2012.  Trend  (for  IPD  cases
from  2003  to 2012)  and  logistic  regression  analyses  (2007–2010)  were  performed  to identify  changes
in  serotype  distribution  and  to identify  the association  of serotypes  with  age,  clinical  manifestations,
comorbidities  and  case  fatality,  respectively.
Findings:  The  proportion  of  PCV7  serotypes  among  all IPD  cases  (n =  7678)  signiﬁcantly  declined  in  adults
from  44.7%  (2003)  before  to 16.7%  (2012)  after  the  recommendation  of  PCV7  (P < 0.001).  In  contrast,
the  proportion  of non-PCV7  serogroup/serotypes  increased  for non-PCV13  but also  PCV13  serotypes
(not  included  in  PCV7)  at the  same  time.  Serotype  distribution  varied  signiﬁcantly  across  ages,  clinical
manifestations  and comorbidities.  Serotype  was  furthermore  associated  with  case  fatality  (P  = 0.001).
In  a multivariable  logistic  regression  model,  analyzing  single  serotypes  showed  that  case-fatality  was
increased  for  the  serotypes  3  (P = 0.008),  19A (P =  0.03)  and  19F (P =  0.005),  compared  to serotype  1 and
7F.
Conclusion:  There  was  a signiﬁcant  decline  in  PCV7  serotypes  among  adults  with  IPD in Switzerland  after
introduction  of childhood  vaccination  with PCV7.  Pneumococcal  serotypes  were  associated  with case
fatality,  age,  clinical  manifestation  and comorbidities  of IPD in  adults.  These  results  may  prove  useful  for
future  vaccine  recommendations  for adults  in Switzerland.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
Invasive pneumococcal infections (IPD) are among the most
mportant vaccine-preventable infections in humans causing sig-
iﬁcant morbidity and mortality world-wide [1]. The risk of IPD
s highest at the extremes of age and in patients suffering from
omorbidities [2].
∗ Corresponding author at: Institute for Infectious Diseases, University of Bern,
riedbühlstrasse 51, Postfach 61, CH-3010, Switzerland. Tel.: +41 31 632 4983;
ax: +41 31 632 8766.
E-mail address: Markus.Hilty@iﬁk.unibe.ch (M.  Hilty).
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
At the beginning of the 21st century, the heptavalent conjugated
pneumococcal polysaccharide vaccine (PCV7) became available –
covering the serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Addition
of PCV7 to the infant vaccination schedules has greatly reduced
IPD and non-invasive pneumonia in vaccinated infants at different
geographical sites [3,4]. Serotype redistribution caused by vaccine
selection pressure and probably other, yet unknown factors, have
necessitated an enlargement of the vaccine’s serotype spectrum.
PCV13, covering in addition the serotypes 1, 3, 5, 6A, 7F, and 19A,
has recently become available and is now replacing PCV7 in many
countries worldwide. In some countries like the USA, Canada and,
to a lesser extent, in England and Wales, adults were found to
proﬁt from indirect protection (i.e. ‘herd immunity’) due to high
PCV7 vaccination coverage in infants [2,5–7]. In other European
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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ountries such as Spain, the Netherlands and France, this beneﬁt
ould not be observed that clearly [4,8]. As for Switzerland, no such
ffect was described 3 years after introduction of PCV7 in a recent,
ooled analysis of multiple surveillance sites [9]. The reason for a
ack of measurable herd effects in some countries may  be due to a
ow vaccination coverage or a rapid and important serotype redis-
ribution resulting in the emergence of non-PCV7 serotypes such
s 1, 3, 7F, 19A and others [4]. However, the mechanism by which
his redistribution takes place is largely unknown and introduction
f new strains and/or capsule switch due to recombination among
xisting strains is possible [10,11].
In 2001 PCV7 vaccination was recommended for children <5
ears at increased risk for IPD. In November 2005, PCV7 vaccina-
ion became recommended for all children younger than 2 years
n Switzerland which included a 2 + 1 dosing schedule at 2, 4 and
2 months without catch-up campaign. According to the Swiss
ational Vaccination Coverage Survey, the vaccine coverage was
bout 53% for one dose, 50% for 2 doses and 37% for 3 doses at the
ge of 2 years in 2008–2010 [12]. In 2005–2007, the PCV7 cover-
ge was only about 2% for the ﬁrst dose. Since 2011, PCV13 replaces
CV7. In addition, the 23-valent pneumococcal polysaccharide vac-
ine (PPV23) has been recommended for individuals aged ≥65 years
r those ≥2 years with known risk factors for IPD since 2000 [13].
owever, the protection efﬁcacy of the currently used PPV23 seems
o be limited [14]. This raises the question whether PCV13 could
eplace or supplement PPV23 vaccination in these two age groups
n Switzerland. Apart from prospective efﬁcacy studies, this deci-
ion should in part be based on the age-dependent IPD serotype
pidemiology, too. The main objective of this study is thus the
escription of the current serotype epidemiology of IPD in adult
wiss residents. The speciﬁc objectives are: (i) analysis of tempo-
al trends of single serotypes, (ii) association of serotypes with age
nd clinical manifestations, (iii) association of serotypes with type
nd number of different comorbidities and (iv) correlation between
erotype and case-fatality.
. Material and methods
.1. Data collection
In Switzerland, IPD notiﬁcation to the Federal Ofﬁce of Public
ealth (FOPH) is mandatory for laboratories and physicians within
ne week after IPD conﬁrmation. Using a standardized IPD repor-
ing form, information on age, gender, vaccination history, clinical
anifestation of IPD, comorbidities and death are collected. No
atient follow up took place.
Clinical manifestations of IPD to be ticked on the form included
nvasive pneumonia, meningitis, sepsis and ‘others’ accompa-
ied by a free-text line. If patients were reported to suffer
rom sepsis only, we subsequently attributed ‘bacteremia with-
ut focus’ to this group. Patients with pneumonia (including
mpyema) may  simultaneously present with other clinical mani-
estations. If cases presented with both pneumonia and meningitis,
atients were only accounted for the latter. Other manifestations
ncluded arthritis and the ones noted by the physician as free
ext.
Comorbidities reported on the forms included chronic kidney
isease, immunosuppression, recurring airway diseases, recur-
ing otitis, splenectomy, nephrotic syndrome, basal skull fracture,
hronic lung diseases, diabetes mellitus, functional asplenia, cere-
rospinal ﬁstula and ‘others’ accompanied by a free-text line. The
atter were investigated and were assigned to cancer (including
ematological malignancy, with and without current chemother-
py), heart disease, liver disease, HIV, transplantation, nicotine and
lcohol abuse.
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Comorbidities were grouped into three main categories; (i)
chronic disease, (ii) immunosuppression and (iii) underlying respi-
ratory disease. In brief, ‘chronic disease’ included reported chronic
kidney disease, nephrotic syndrome, diabetes mellitus, heart and
liver disease. ‘Immunosuppression’ included reported immuno-
suppression, splenectomy/hemoglobinopathy, cancer, HIV and
transplantation. ‘Underlying respiratory disease’ contained recur-
rent airway disease, recurrent otitis, chronic lung disease and
nicotine abuse. Patients could belong to multiple categories.
All clinical microbiology laboratories are asked to send isolates
of Streptococcus pneumoniae from a sterile site to the National Ref-
erence Laboratory for Invasive Pneumococcal Disease (NZPn).
At the NZPn, isolates were conﬁrmed as S. pneumoniae using
alpha hemolysis morphology on blood agar plates, bile solubility,
optochin sensitivity and molecular typing [15]. Serotypes of con-
ﬁrmed S. pneumoniae were determined by the Quellung reaction.
For the serotype trend analysis, all adult Swiss residents ≥16
years with culture-conﬁrmed IPD of known serotype and which
were notiﬁed during 2003–2012 were included. If a patient suffered
from more than one IPD episode per calendar year, only the ﬁrst was
included in the analysis. As for this time period, 8698 cases were
registered at the FOPH. Of these, 659 (84%), 733 (86%), 783 (89%),
743 (89%), 798 (88%), 871 (90%), 893 (88%), 719 (92%), 776 (90%)
and 703 (86%) cases could be linked with pneumococcal serotype
isolate collected at the NZPn, in 2003, 2004, 2005, 2006, 2007, 2008,
2009, 2010, 2011 and 2012, respectively.
For the investigation of the effect of serotype/serogroup on
various outcomes, all adult Swiss residents ≥16 years with culture-
conﬁrmed IPD of known serotype and which were notiﬁed during
2007–2010 were included.
The IPD surveillance is part of the governmental public health
surveillance based on the law for epidemics and is therefore
exempted from approval by Institutional Review Boards.
2.2. Statistical analysis
Temporal changes from 2003 to 2012 were analyzed
using the Cochran–Armitage test for trend and P < 0.05 was
considered as being statistically signiﬁcant. The dynam-
ics of serotypes/serogroups were also evaluated using the
Cochran–Armitage test as previously described [16]. Differences
in the proportions of pneumococcal serotypes in adult patients
with and without PPV23 were tested using 3 × 2 and 2 × 2 2-test,
respectively (the latter excluding patients for whom vaccination
status were not available).
Incidence of IPD cases with known serotype from 2007 to 2010
were calculated and stratiﬁed by age, clinical manifestation, comor-
bidities and death. The Swiss population aged ≥16 years was 6.3,
6.4, 6.5 and 6.6 million for 2007, 2008, 2009 and 2010 respectively
[17].
The effect of serotype/serogroup on various outcomes was
investigated by multivariable logistic regression analyses. The
included outcomes were:
(i) Age group (16–64 versus ≥65 years), adjusted for number of
comorbidities (0 versus ≥1), clinical manifestation (meningitis,
bacteremia without focus and pneumonia) and sex.
ii) Death (yes versus no/not reported), adjusted for age, number of
comorbidities, clinical manifestation and sex.
iii) Bacteremia without focus (yes versus no), adjusted for age,
number of comorbidities and sex.iv) Presence versus absence of different comorbidities (0 versus
≥1), adjusted for age, clinical manifestation and sex.
(v) Presence versus absence of immunosuppression adjusted for
age, clinical manifestation and sex.
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Adjusted odds ratio (OR) estimates with 95% conﬁdence inter-
als (95%CIs) were calculated and signiﬁcance of overall association
as tested using a two-tailed Likelihood Ratio (LR) test. For all
ogistic regression analyses, the serotypes 1 and 7F were grouped
ogether and served as the reference group. These serotypes have
een described to infect mainly young individuals with few comor-
idities and have been previously used as reference serotypes
18–21].
Logistic regression analysis was performed using Stata version
1 (Stata Corporation, College Station, TX, USA). Cochran–Armitage
est for trend was done with EPI INFO Version 3.4.1 (Centre for
isease Control and Prevention (CDC), Atlanta, GA).
. Results
This study included 7678 IPD patients aged ≥16 years notiﬁed
o the FOPH with linked pneumococcal isolate serotype infor-
ation in Switzerland from 2003 to 2012 (Table 1). In total
wenty serotypes/serogroups with an overall proportion of ≥1%
ere detected. The proportions of 6 of 7 PCV7 serotypes sig-
iﬁcantly decreased (serotypes 4, 14, 19F, 23F, 6B and 9V) over
ime while for the remaining (serotype 18C), a decline was also
oted albeit not signiﬁcant. In contrast, the proportion of non-
CV7 serogroup/serotypes increased for non-PCV13 (22, 15, 23,
5 and others) but also PCV13 not included in PCV7 (3, 7F,
9A) serotypes. As for serotypes/serogroups with proportions
1%, only for serotype 6C a signiﬁcant increase was observed
Table 1).
This study then investigated 3281 IPD patients notiﬁed to the
OPH with linked pneumococcal serotype isolate information in
witzerland from 2007 to 2010 in more detail (Table 2). The mean
ge was 65.4 years (SD 17.4) and there were 1.3 times (95%CI:
.2–1.4) more female (n = 1841; 56.1%; 95%CI: 54.4–57.8%; Table 2)
able 1
erotypes of S. pneumoniae causing invasive pneumococcal disease (IPD) in patients aged
Serotype/
serogroup
Coverage by
the vaccineb
IPD cases with serotype and clinical information known
Year 
2003 2004 2005 2006 20
4 7, 13 62 (9.4) 49 (6.7) 66 (8.4) 71 (9.6) 56
6B  7, 13 27 (4.1) 22 (3.0) 31 (4.0) 31 (4.2) 28
9V  7, 13 31 (4.7) 44 (6.0) 55 (7.0) 44 (5.9) 62
14  7, 13 107 (16.2) 115 (15.7) 105 (13.4) 104 (14.0) 10
18C  7, 13 14 (2.1) 17 (2.3) 22 (2.8) 24 (3.2) 30
19F  7, 13 21 (3.2) 22 (3.0) 28 (3.6) 37 (5.0) 35
23F  7, 13 33 (5.0) 40 (5.5) 51 (6.5) 48 (6.5) 50
1  13 26 (3.9) 43 (5.9) 35 (4.5) 29 (3.9) 27
3  13 83 (12.6) 85 (11.6) 104 (13.3) 79 (10.6) 96
7F  13 48 (7.3) 67 (9.1) 61 (7.8) 59 (7.9) 78
19A  13 18 (2.7) 25 (3.4) 20 (2.6) 16 (2.2) 30
6Ad 13 14 (2.1) 24 (3.3) 22 (2.8) 31 (4.2) 32
8  31 (4.7) 36 (4.9) 52 (6.6) 53 (7.1) 28
10  10 (1.5) 8 (1.1) 6 (0.8) 9 (1.2) 6 (
11  16 (2.4) 14 (1.9) 18 (2.3) 11 (1.5) 11
22e 19 (2.9) 29 (4.0) 22 (2.8) 24 (3.2) 24
6Cd ND ND ND ND 2 (
9  30 (4.6) 25 (3.4) 23 (2.9) 15 (2.0) 20
15  10 (1.5) 8 (1.1) 6 (0.8) 12 (1.6) 8 (
23  12 (1.8) 4 (0.5) 4 (0.5) 10 (1.3) 5 (
35  ND 7 (1.0) 7 (0.9) 7 (0.9) 6 (
Othersa 47 (7.1) 49 (6.7) 45 (5.7) 29 (3.9) 55
Total  659 (100) 733 (100) 783 (100) 743 (100) 79
a All serotypes/serogroups with an overall proportion of <1% were combined to one gro
b Coverage by the vaccine PCV7 (7) and PCV13 (13). PPV23 serotypes are 1, 2, 3, 4, 5, 6B
c Exact P values for Cochran–Armitage 2 test of trend. P < 0.05 is indicated in bold.
d Isolates of serogroup 6 were not differentiated into 6A or 6C for 2003–2006.
e Isolates of serogroup 22 were differentiated into 22F and non-22F serotypes in 2007–
solates  of 22F were received.
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than male patients. For the majority of these patients, clinical man-
ifestations were known (n = 3054; 93.1%), with pneumonia being
the most frequent unique manifestation (n = 2347). Clinical infor-
mation on manifestation and comorbidities was available for 2854
cases, with 1210 cases aged 16–64 years and 1644 aged ≥65 years
for 2007–2010. Number and incidence of serotyped IPD (cases with
known serotype and clinical information per 100,000 population)
detected from 2007 to 2010 decreased overall (Chi Square for trend;
P = 0.01). The decrease was  pronounced in those aged ≥65 years,
those with pneumonia and those with comorbidities. The over-
all case-fatality rate was 11.4% with signiﬁcant decrease within
2007–2010 (P = 0.03; Table 2). Table 3 compares IPD cases in PPV23
vaccinated (n = 82) and non-vaccinated (n = 1682) individuals from
2007 to 2010. Results showed a signiﬁcantly lower proportion of
PPV23 serotypes in vaccinated adults (P < 0.001) (Table 3). In con-
trast, an increase of serotype 6A (P < 0.001), which is not included
in PPV23, was  noted.
In order to investigate any correlation between the differ-
ent serotypes/serogroups and age, two-tailed Likelihood Ratio
(LR) and a multivariable logistic regression was performed.
Serotype/serogroup was  signiﬁcantly associated with age (≥65
years; P < 0.001). Subsequent single serotype analysis showed that
cases with serotypes/serogroups 6A, 23F, 6B, 11, 14 and 15 infection
were most signiﬁcantly (OR > 2) associated with the age ≥65 years
compared to those infected with the serotypes of the reference
group (1 and 7F) (Fig. 1A).
Serotype was  also associated with case fatality (P = 0.001) and
scrutinizing the individual serotypes revealed that serotypes 3, 19A
and 19F were saliently associated with increased case-fatality, com-
pared to the reference group (Fig. 1B).
As for the manifestations, suffering from pneumonia (P < 0.001),
meningitis (P < 0.01) and bacteremia without focus (P < 0.01) was
associated by serotype, too. IPD due to serotypes/serogroups 35,
 ≥16 years, Switzerland (2003–2012).
, no. (%)
Pc
07 2008 2009 2010 2011 2012
 (7.0) 68 (7.8) 66 (7.4) 45 (6.3) 38 (4.9) 25 (3.6) <.001
 (3.5) 20 (2.3) 17 (1.9) 13 (1.8) 18 (2.3) 9 (1.3) <.001
 (7.8) 54 (6.2) 44 (4.9) 19 (2.6) 13 (1.7) 11 (1.6) <.001
9 (13.7) 87 (10.0) 76 (8.5) 47 (6.5) 45 (5.8) 25 (3.6) <.001
 (3.8) 16 (1.8) 14 (1.6) 20 (2.8) 14 (1.8) 9 (1.3) .06
 (4.4) 32 (3.7) 24 (2.7) 17 (2.4) 19 (2.4) 8 (1.1) .002
 (6.3) 54 (6.2) 50 (5.6) 22 (3.1) 20 (2.6) 26 (3.7) <.001
 (3.4) 31 (3.6) 37 (4.1) 35 (4.9) 23 (3.0) 26 (3.7) .1
 (12.0) 121 (13.9) 129 (14.4) 99 (13.8) 131 (16.9) 109 (15.5) <.001
 (9.8) 72 (8.3) 90 (10.1) 77 (10.7) 83 (10.7) 78 (11.1) .001
 (3.8) 35 (4.0) 53 (5.9) 65 (9.0) 92 (11.9) 80 (11.4) <.001
 (4.0) 29 (3.3) 31 (3.5) 23 (3.2) 15 (1.9) 17 (2.4) .5
 (3.5) 47 (5.4) 45 (5.0) 37 (5.1) 46 (5.9) 41 (5.8) 0.8
0.8) 13 (1.5) 11 (1.2) 6 (0.8) 15 (1.9) 13 (1.8) .2
 (1.4) 24 (2.8) 21 (2.4) 11 (1.5) 19 (2.4) 13 (1.8) 1.0
 (3.0) 28 (3.2) 46 (5.2) 51 (7.1) 54 (7.0) 48 (6.8) <.001
0.3) 4 (0.5) 9 (1.0) 15 (2.1) 16 (2.1) 15 (2.1) <.001
 (2.5) 37 (4.2) 24 (2.7) 28 (3.9) 27 (3.5) 29 (4.1) .6
1.0) 17 (2.0) 14 (1.6) 17 (2.4) 18 (2.3) 21 (3.0) <.001
0.6) 11 (1.3) 14 (1.6) 10 (1.4) 13 (1.7) 17 (1.4) .01
0.8) 8 (0.9) 12 (1.3) 13 (1.8) 5 (0.6) 16 (2.3) .03
 (6.9) 63 (7.2) 66 (7.4) 49 (6.8) 52 (6.7) 67 (9.5) .02
8 (100) 871 (100) 893 (100) 719 (100) 776 (100) 703 (100)
up (“others”), with the exception of serotype 6C which is listed separately.
, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.
2012. In total, 22 (2007), 26 (2008), 45 (2009), 47 (2010), 53 (2011) and 48 (2012)
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Table 2
Characteristics of the study population: patients aged ≥16 years with invasive pneumococcal disease of known serotype after the introduction of PCV7, Switzerland
(2007–2010).
No. of cases with known serotype and clinical information per calendar year (no. of cases per 100,000 population)
2007 2008 2009 2010 Pa
Total cases ≥16 years notiﬁed 912 971 1012 784
Total  cases ≥16 years with known serotype 798 (12.6) 871 (13.5) 893 (13.7) 719 (10.9) 0.01
Age  group
16–49 years 156 (4.3) 187 (5.1) 179 (4.8) 136 (3.6) 0.1
50–64  years 170 (11.8) 187 (12.8) 215 (14.4) 163 (10.8) 0.7
≥65  years 472 (38.0) 497 (38.9) 499 (38.1) 420 (31.6) 0.007
Deaths within 90 days 100 (1.6) 100 (1.6) 99 (1.5) 74 (1.1) 0.03
Clinical manifestation knownb 755 806 818 675
Pneumoniac 589 (9.3) 606 (9.4) 637 (9.8) 515 (7.8) 0.01
Meningitisc 42 (0.7) 49 (0.8) 41 (0.6) 31 (0.5) 0.1
Bacteremia w/o  focus 89 (1.4) 97 (1.5) 86 (1.3) 84 (1.3) 0.4
Othersd 35 (0.6) 54 (0.8) 54 (0.8) 45 (0.7) 0.5
Comorbidities knowne 715 766 767 621
0  220 (3.5) 250 (3.9) 264 (4.1) 215 (3.3) 0.6
≥1  496 (7.8) 516 (8.1) 503 (7.7) 406 (6.1) <0.001
a P-values for Cochran–Armitage 2 test of trend.
b Clinical manifestations were not known for 5.4%, 6.7%, 8.4% and 6.1% of patients for 2007, 2008, 2009 and 2010, respectively.
c Patients who  presented with both pneumonia and meningitis are listed with meningitis.
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eritonitis, empyema).
e Comorbidities were not known for 10.4%, 12.1%, 14.1% and 12.6% of patients for
3, 19F and 15 infection were clearly (OR > 2) associated with a bac-
eremia without focus compared to infection with a reference group
erotype 1 and 7F (Fig. 2A). In addition, meningitis was  associated
ith serotypes 35, 15, 11, 18C and 23F (OR > 6) compared to the
eference group. These ﬁndings were independent of age, sex and
umber of comorbidities. As for pneumonia, none of the serotypes
as more likely than the chosen reference group. In more detail,
erotypes 15, 35, 18C, 19F, 23, 23F, 6B and 11 were the rarest and
esulted in OR < 0.5.
As for morbidity, serotype was associated with different num-
ers of comorbidities (i.e. having at least one versus no comorbidity;
 < 0.001). Results displayed that cases infected with serotypes
ther than serogroup 8 suffered from one or more comor-
idities signiﬁcantly more often than those infected with the
erotypes of the reference group (1 and 7F) (Fig. 2B). Among these
erotypes/serogroups OR were highest for 23, 35, 6B, 19F and 20.
f those, serogroups 20 and 35 are neither covered by PCV7 nor
CV13.
Regarding type of comorbidity, immunosuppression (P < 0.001)
ut not chronic diseases (P = 0.2) and pre-existing underlying respi-
atory disease (P = 0.4) were signiﬁcantly associated with serotype
able 3
roportions of pneumococcal serotypes in adult patients with and without 23-valent pne
Serotype/serogroupa Vaccine coverageb PPV23 vaccinated (n = 82) Not vac
14 7, 13 5 (6.1) 169 (1
18C  7, 13 3 (3.7) 36 (2
19F  7, 13 1 (1.2) 55 (3
23F  7, 13 3 (3.7) 100 (5
4  7, 13 3 (3.7) 132 (7
6B  7, 13 1 (1.2) 41 (2
9V  7, 13 6 (7.3) 97 (5
1  13 0 (0.0) 80 (4
19A  13 7 (8.5) 94 (5
3  13 8 (9.8) 224 (1
7F  13 6 (7.3) 169 (1
6A  13 9 (11.0) 50 (2
All  PPV23 serotypes 52 (63.4) 1399 (8
a PCV13 serotypes/serogroups are illustrated (with the exception of serotype 5).
b Vaccine coverage is indicated for PCV7 (7), and PCV13 (13). PPV23 serotypes are 1, 2, 
3F.
c 3 × 2 2-test. P < 0.05 is indicated in bold.
d 2 × 2 2-test (excluding patients for whom vaccination status were not available (NAe physicians (amongst others otitis, mastoiditis, sinusitis, epiglottitis, endocarditis,
, 2008, 2009 and 2010, respectively.
using the two-tailed Likelihood Ratio (LR) test. As for the ﬁrst, cases
infected with serotypes/serogroups other than 4 and 8 were more
often immunocompromised than those infected with the serotypes
of the reference group (1 and 7F) (Fig. 2C).
4. Discussion
This population-based study evaluates the serotype epidemiol-
ogy of invasive S. pneumoniae isolates, from 2003 to 2012 including
association of causing serotype with IPD characteristics and case-
fatality in adult Swiss residents aged ≥16 years reported from 2007
to 2010. The study period for the latter covered the years after rec-
ommendation of the complementary vaccination with PCV7, but
before recommendation of PCV13 for infants [13,22]. During that
period, 920 of about 6.5 million Swiss residents aged ≥16 years
were diagnosed with an IPD per year in mean (i.e. 14.2/100,000). It
was possible to link approximately 90% of reported IPD cases with a
corresponding pneumococcal isolate. Therefore, the completeness
of this linkage was  very high indicating a very high participation of
involved laboratories.
umococcal polysaccharide vaccine (PPV23).
cinated (n = 1698) NA (n = 1490) P (3 × 2)c P (2 × 2) (excluding NA)d
0.0) 143 (9.6) 0.49 0.25
.1) 38 (2.6) 0.53 0.35
.2) 55 (3.7) 0.43 0.31
.9) 68 (4.6) 0.20 0.40
.8) 101 (6.8) 0.25 0.25
.4) 35 (2.4) 0.78 0.49
.7) 81 (5.4) 0.80 0.54
.7) 46 (3.1) 0.01 0.04
.5) 85 (5.7) 0.50 0.25
3.2) 201 (13.5) 0.62 0.40
0.0) 143 (9.6) 0.70 0.40
.9) 58 (3.9) <0.001 <0.001
2.4) 1187 (79.7) <0.001 <0.001
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and
)). P < 0.05 is indicated in bold.
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Fig. 1. Multivariable logistic regression analysis. Association analysis of
serotype/serogroup with (A) patient’s age (≥65 years) and (B) death. Odds
ratios (OR) were adjusted for age categories, number of comorbidities and
clinical manifestation (bacteremia without focus, pneumonia and meningitis).
Serotypes/serogroups with proportion of <1% were combined to one group (other)
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Fig. 2. Multivariable logistic regression analysis. Association analysis of
serotype/serogroup with the patients having (A) bacteremia without focus,
(B) having one or more comorbidities and (C) being immunocompromised.
Odds ratios (OR) were adjusted for age categories, sex and clinical manifestation
(bacteremia without focus, pneumonia and meningitis). Serotypes/serogroups with
proportion of <1% were combined to one group (other) for the analysis but omitted
in  the graphs. For the analysis, the serotypes 1 and 7F were grouped and served as
reference. Serotypes are sorted according to OR and 95% conﬁdence intervals areor  the analysis but omitted in the graphs. For the analysis, the serotypes 1 and 7F
ere grouped and served as reference. Serotypes are sorted according to OR and
5%  conﬁdence intervals are shown.
During 2007–2010, incidence of IPD cases with known serotype
as changed signiﬁcantly in adults overall and in those ≥65 years
n Switzerland. In addition, this study shows a changing serotype
istribution of invasive S. pneumoniae isolates from 2003 to 2012.
his has been described for the PCV7 versus non-PCV7 serotypes
ecently [9] but our study additionally shows the single serotype
pidemiology in Switzerland. The sharp increase of the non-PCV7
erotype 19A is remarkable and has also been observed in other
ountries [6,23–25]. However, it is not clear if the introduction
f PCV7 is exclusively responsible for this observation [26,27]. A
igniﬁcant increase of other non-PCV7 serogroups/serotypes was
etected which countered the drop of vaccine serotypes to a certain
xtent. Increasing numbers of isolates of serotypes 19A, 22F and 6C
ut not of serogroup 35 have also been described in a study per-
ormed at the University Hospitals in Cleveland during 1999–2007
28].It is well known that IPD incidence rates increase with advanc-
ng age and with various comorbidities like immunosuppression,
nderlying respiratory diseases and chronic diseases [29]. Hence
PV23 vaccination was recommended for persons with increased
shown.
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isk for IPD (i.e. for those aged 65 years and older and those older
han 2 years with known risk factors for IPD) in Switzerland. How-
ver, despite the broad vaccine usage, the efﬁcacy of PPV23 is
enerally described as being poor at least in preventing pneumonia
14]. These issues cannot be conﬁrmed or dismissed with our data
ut in those with a known PPV23 vaccination history, vaccinated
atients had a lower proportion of IPD due to PPV23 serotypes,
hereas the non-PPV23 serotype 6A was associated with previous
PV23 vaccination.
This study identiﬁed individual serotypes which mainly caused
PD in elderly adults and/or in adults with comorbidities. Unfor-
unately, a few of those serotypes/serogroup are not covered, by
CV13 e.g. serogroups 15, 20 and 35. The latter showed an increas-
ng trend from 2007 to 2010 and may  therefore become more
mportant in the future. Our study also illustrates that the serotype
as related to the clinical manifestations which was also investi-
ated in a previous study in the Netherlands [30].
A recent population based study from Denmark demon-
trated that patients aged 5 years and older infected with
erotypes/serogroups 31, 11A, 35F, 17F, 3, 16F, 19F, 15B or 10A
ore often died than those infected with serotype 1, from 1977 to
007 [20]. A study performed during the ﬁrst 4 years after introduc-
ion of PCV7 in the United States showed in addition that patients
ged >50 years with serotype/serogroup 3, 11A 19F or 23F infection
ore often died than those with serotype 14 infection [2]. Consis-
ent with our results, both of these studies conﬁrmed the high case
atality of IPD due to serotype 3 and 19F. However, many other
tudies which analyzed death due to individual serotypes were
one before the introduction of PCV7 making a comparison with
ur study challenging [18,30]. As for our setting, considering that
he serotypes 3, 19A and 19F are associated with the highest case
atality, the PCV13 vaccination might be indeed of advantage for
dults at increased risk for IPD in Switzerland as those serotypes
re included in PCV13. However it can also be expected that the
ntroduction of PCV13 within infants will affect the epidemiology
f pneumococcal serotypes within adults which has already been
oted within other countries but not yet Switzerland.
Our study has several limitations. By including only serotypes
ith an overall proportion of ≥1% (with the exception of serotype
C), some serotypes were neglected which have also signiﬁcantly
isen but have just not yet reached large enough numbers. In
ddition, data about case fatality may  be incomplete as the physi-
ians have to report IPD to the FOPH within one week after IPD
onﬁrmation but some IPD patients may  die after reporting. No
atient follow up took place. In general, no validation of the qual-
ty of data was performed for this study. Therefore, variation in the
eﬁnition criteria to report e.g., a chronic lung disease, diabetes
r nicotine abuse could have biased our results. A random mis-
lassiﬁcation would have produced an underestimation of a true
ssociation while selective misclassiﬁcation could have induced a
ias in both directions. Finally, the multivariable logistic regression
nalyses we performed allow to adjust for possible confounding by
ge, sex and comorbidities of the association of serotype/serogroup
ith the analyzed outcomes, but are not capturing the more com-
lex biological interactions between host and bacterial factors in
haping the likelihood of the analyzed outcomes. However, our
esults are comparable with similar studies from different settings
2,4,6,20]
In conclusion, this is a very detailed population based IPD
urveillance study in adults. It documents that IPD case fatality,
ge (≥65 years), type of manifestation (pneumonia, meningitis and
acteremia without focus), number (≥1) and type of comorbidities
immunosuppression) are signiﬁcantly and independently associ-
ted with serotype. It furthermore identiﬁes the single serotypes
riving these observations (e.g., 3, 19A and 19F for case fatal-
ty). The results may  therefore help as an epidemiological basis
[
[2 (2014) 5185–5191
for future vaccination recommendations to prevent IPD in distinct
adult groups at risk in Switzerland.
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